Welcome to our dedicated page for Stemtech SEC filings (Ticker: STEK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Stemtech's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Stemtech's regulatory disclosures and financial reporting.
Stemtech Corporation reported continuing operating losses and severe liquidity pressure for the six months ended June 30, 2026. Net sales were $1,092,269, down from $1,565,971 in 2025, largely due to constrained inventory that limited distributor orders. Gross profit fell to $819,980 and gross margin declined to 75.1%. The company reduced operating expenses to $1,947,976 from $2,778,173, narrowing the operating loss to $1,127,996 and the net loss to $1,453,418.
Total assets were $3,163,559 against current liabilities of $11,112,964, resulting in a working capital deficit of about $10.5 million and a stockholders’ deficit of $8,216,405. Management states that recurring losses, negative cash flows, and dependence on external financing raise substantial doubt about the ability to continue as a going concern. The company relies on convertible notes, a discretionary $7.0 million senior secured convertible facility (of which $1,561,660 has been funded), factoring arrangements, and a new inventory financing agreement.
Capital structure is highly dilutive. Shares outstanding increased from 425,980,711 at December 31, 2025 to 2,738,521,585 at June 30, 2026, and to 2,997,032,856 by August 13, 2026, mainly through conversion of debt and stock issued for services and insider compensation. The company also discloses defaults under merchant cash advance agreements and ongoing litigation with a former CEO, for which $267,000 is accrued.
Stemtech Corporation reports Q1 2026 results with net sales of $462,957, down from $868,046 a year earlier, and a net loss of $1,252,880. Operating expenses fell by $477,267, and interest expense declined, narrowing the loss by about 14% year over year.
The balance sheet remains highly strained, with current liabilities of $11.1M versus current assets of $0.6M, creating a working capital deficit of about $10.5M and an accumulated deficit of roughly $36M. Management again raises substantial doubt about the company’s ability to continue as a going concern and highlights dependence on external financing, including a discretionary senior secured convertible facility and related-party loans.
Share count rose sharply to 1.65 billion at March 31, 2026 and 2.37 billion by June 22, 2026, mainly from stock issued for services and conversions of debt into equity, significantly diluting existing holders. Subsequent inventory financing of roughly $2.5M is intended to rebuild product availability and support future sales.
Stemtech Corporation reports another challenging year in its latest annual report. Net sales for 2025 fell to $2,876,380 from $5,053,690 in 2024 as product stock-outs and working capital constraints hurt revenue. The company posted a net loss of $4,049,840, slightly deeper than the prior year, and current liabilities of $10,587,013 far exceeded current assets of $457,062, leaving a significant working capital deficit.
Auditors issued a going concern warning, citing recurring losses, capital deficiency and dependence on external financing. Stemtech’s stockholders’ deficit widened to $7,704,399, while common shares outstanding jumped from 135,756,053 to 425,980,711 during 2025 and to 2,067,960,034 by May 26, 2026 due to large convertible debt conversions, resulting in substantial dilution. The company is also in default under certain merchant cash advance agreements and relies heavily on a $7,000,000 senior secured convertible facility from Leviston Resources, of which only $1,561,660 had been funded by year-end at the lender’s discretion.
Stemtech Corporation submitted a Rule 12b-25 notice stating its Form 10-Q for the quarter ended March 31, 2026 could not be filed on time because the company needs additional time to complete the financial statements and prepare the Form 10-Q. The company states it expects to use no more than the additional five calendar days allowed to complete and file the report.
The notice also discloses that the company has not filed its Annual Report on Form 10-K for the fiscal year ended 2025. The 12b-25 was signed by CEO Charles S. Arnold on May 14, 2026.
STEMTECH CORPORATION notified the SEC that its Form 10-Q for the quarter ended March 31, 2026 was not filed on time and expects to use the additional 5 calendar days permitted under Rule 12b-25 to complete and file the report. The notification was signed by Charles S. Arnold, CEO on May 14, 2026.
Stemtech Corporation filed a Form 12b-25 notifying the SEC of a late annual report for the period ended December 31, 2025. The company states the delay was caused by delays in preparation of its annual financial statements. The notice was signed by Charles S. Arnold, CEO on March 31, 2026.
Stemtech Corporation (STEK) reported another loss-making quarter and raised going concern doubts in its Q3 2025 report. For the quarter ended September 30, 2025, net sales were $852,300, down from $1,031,630 a year earlier, as the company shifted away from lower-margin volume toward core markets. Despite lower revenue, cost controls helped reduce operating loss to $339,217 from $716,470, and net loss narrowed to $812,541 from $1,171,405.
For the nine months, sales fell to $2,418,271 from $3,740,000, but net loss improved to $2,567,547 from $3,376,121 as operating expenses declined by about $1.3 million. The balance sheet remains strained: assets were $3,755,801 against current liabilities of $10,301,779, resulting in a stockholders’ deficit of $6,545,978 and a working capital deficit of about $9.2 million.
Management explicitly concluded that substantial doubt about the company’s ability to continue as a going concern is not alleviated, citing recurring losses, negative operating cash flow, dependence on external financing, and defaults under certain Merchant Cash Advance agreements now in litigation. Stemtech is pursuing private equity raises, a proposed convertible debt facility, cost cuts, and international joint ventures to improve liquidity, but these plans are not yet committed or realized.
Stemtech Corporation filed a Form 12b-25 (NT 10-Q) notifying a late filing of its quarterly report for the period ended September 30, 2025. The company cites delays in preparing its quarterly financial statements as the reason.
The notification lists Charles Arnold, CEO, as the signatory and provides a company contact at (954) 715-6000. The notice was signed on November 14, 2025.